Advisor Group Holdings, Inc. Cybin Inc. Transaction History

Advisor Group Holdings, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.26 - $0.46 $2,910 - $5,148	-11,193 Reduced 44.08%	14,200 $3,000
Q1 2024 May 10, 2024	BUY	$0.3 - $0.46 $600 - $920	2,000 Added 8.55%	25,393 $10,000
Q4 2023 Feb 12, 2024	BUY	$0.38 - $0.65 $3,553 - $6,077	9,350 Added 66.58%	23,393 $9,000
Q3 2023 Nov 13, 2023	BUY	$0.29 - $0.63 $130 - $283	450 Added 3.31%	14,043 $7,000
Q2 2023 Aug 10, 2023	SELL	$0.23 - $0.39 $391 - $664	-1,704 Reduced 11.14%	13,593 $5,000
Q1 2023 May 12, 2023	BUY	$0.3 - $0.56 $269 - $502	897 Added 6.23%	15,297 $5,000
Q4 2022 Feb 10, 2023	BUY	$0.26 - $0.64 $650 - $1,600	2,500 Added 21.01%	14,400 $4,000
Q3 2022 Nov 14, 2022	BUY	$0.48 - $1.11 $3,360 - $7,770	7,000 Added 142.86%	11,900 $5,000
Q2 2022 Aug 10, 2022	BUY	$0.41 - $0.88 $820 - $1,760	2,000 Added 68.97%	4,900 $3,000
Q1 2022 May 04, 2022	SELL	$0.74 - $1.22 $684 - $1,128	-925 Reduced 24.18%	2,900 $3,000
Q3 2021 Nov 05, 2021	BUY	$1.83 - $3.18 $6,999 - $12,163	3,825 New	3,825 $8,000

66.1K

Ticker CYBN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 166,120,000
Market Cap $1.65B
Description
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to t...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.